LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy
Authors:
- Maria AnzengruberMAMaria Anzengruber
- Lukas WimmerLWLukas Wimmer
- Raffaela SzucharRSRaffaela Szuchar
- Katharina SkollKSKatharina Skoll
- Michael WirthMWMichael Wirth
- Franz GaborFGFranz Gabor
Open Access
- 13 November 2022
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 180
Abstract
No abstract availableKeywords
Funding Information
- Donau-Universität Krems
This publication has 46 references indexed in Scilit:
- Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical ModificationsMolecular Pharmaceutics, 2012
- Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticlesInternational Journal of Pharmaceutics, 2012
- Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic reviewBJU International, 2012
- Lectin Mediated Biorecognition as a Novel Strategy for Targeted Delivery to Bladder CancerJournal of Urology, 2011
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticlesInternational Journal of Pharmaceutics, 2011
- Urinary pH, cigarette smoking and bladder cancer riskCarcinogenesis, 2011
- Cell biology and physiology of the uroepitheliumAmerican Journal of Physiology-Renal Physiology, 2009
- Gemcitabine in the treatment of advanced transitional cell carcinoma of the urotheliumAnnals of Oncology, 2006
- Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Mediated TransportMolecular Pharmaceutics, 2005